Wilex AG, which has an antibody treatment for renal cell cancer in a pivotal Stage 3 trial along with a companion diagnostic, has successfully completed a €9.93 million rights issue. Wilex is based in Munich, Germany. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
